In:
The Journal of Immunology, The American Association of Immunologists, Vol. 186, No. 1_Supplement ( 2011-04-01), p. 167.16-167.16
Abstract:
Type 1 diabetes is an autoimmune disease which are mainly caused by the autoimmune destruction of pancreatic islets. One of the most effective immunotherapy for type 1 diabetes (T1D) relies on the induction of peripheral tolerance. Accumulating data show that myeloid-derived suppressor cells (MDSCs) can suppress immune response through multiple strategies. In the study, we first showed MHC-dependent Ag presentation is required in MDSC-mediated Treg induction or T-cells suppression. The mechanism of action of MDSCs included the secretion of anti-inflammation cytokines, induction of CD4+CD25+Foxp3+ Treg and suppression of T-cell proliferation to create immune tolerance. Next, we examined the role of MDSCs in murine models. Adoptive transfer of MDSCs reduced diabetes by 75% compared with control group in RIP-HA/Rag2-/- mice. We further confirmed the protective role of MDSCs in NOD/scid mice. NOD/scid mice were injected with inflammatory T cells from diabetic NOD mice in the presence of MDSCs. Consistently, single-dose treatment of MDSCs showed significant long-term protection (60% remained diabetes free) and the protection effect is dose-dependent. Overall, the data suggest that MDSCs can suppress T1D via regulation of T cell-mediated tolerance. MDSCs have great potential to treat T1D and other autoimmune diseases.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.186.Supp.167.16
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2011
detail.hit.zdb_id:
1475085-5
